


Figure S3. Exposure-Response Relationships Between Risankizumab Plasma C_{avg} and Safety Events of Interest Over the First 16 Weeks



Note: C_{avg} represents average concentration from week 0 to 16

Median of C_{avg} ($\mu\text{g/mL}$): Quartile 1 = 4.76 $\mu\text{g/mL}$, Quartile 2 = 6.57 $\mu\text{g/mL}$, Quartile 3 = 8.02 $\mu\text{g/mL}$, Quartile 4 = 10.13 $\mu\text{g/mL}$.

As shown in Figure S3, the incidence of any infection and infestation over the first 16-week treatment period (week 0-16) was slightly higher for risankizumab than placebo; however, no exposure-related trend was noted among subjects who received risankizumab treatment.